PTGXProtagonist Therapeutics, Inc.

PTGX Stock Price, Valuation & Chart | Protagonist Therapeutics, Inc.

Compare

$146.49-1.26 (-0.85%)

At close · 01 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology PTGX intrinsic value PTGX calculated fair value vs price

Overview Financials Dividends Ratios

PTGX Historical price chart

PTGX Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization9.42B

PE Ratio142.22

EPS1.03

Trading Volume534.12K

Today's High/Low150.35/144.73

Dividend Yield0.00

52 Week High/Low160.81/54.5

Shares Outstanding64.31M

PTGX Financial Statement

PTGX Analyst ratings

PTGX Analysis & performance metrics

PTGX Company profile

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and…

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary…

PTGX Management team

Name

Position

Asif AliCFO

Executive Vice President & Chief Financial Officer

Mohammad Masjedizadeh Ph.D.CTO

Executive Vice President & Chief Technology Officer

Suneel K. Gupta Ph.D.

Executive Vice President of Clinical Development

Newman Yeilding

Executive Vice President, Chief Scientific Officer

Carena Spivey

Head of HR & Senior Vice President of Human Resources

Ashok Bhandari Ph.D.

EVice President & Chief Discovery Officer

Carter J. King

Executive Vice President of Business Development

Matthew M. Gosling J.D.

Executive Vice President & General Counsel

Name

Position

Asif AliCFO

Executive Vice President & Chief Financial Officer

Mohammad Masjedizadeh Ph.D.CTO

Executive Vice President & Chief Technology Officer

Suneel K. Gupta Ph.D.

Executive Vice President of Clinical Development

Newman Yeilding

Executive Vice President, Chief Scientific Officer

Carena Spivey

Head of HR & Senior Vice President of Human Resources

Ashok Bhandari Ph.D.

EVice President & Chief Discovery Officer

Carter J. King

Executive Vice President of Business Development

Matthew M. Gosling J.D.

Executive Vice President & General Counsel

Management Team

Asif AliCFO

Executive Vice President & Chief Financial Officer

Mohammad Masjedizadeh Ph.D.CTO

Executive Vice President & Chief Technology Officer

Suneel K. Gupta Ph.D.

Executive Vice President of Clinical Development

Newman Yeilding

Executive Vice President, Chief Scientific Officer

Carena Spivey

Head of HR & Senior Vice President of Human Resources

Ashok Bhandari Ph.D.

EVice President & Chief Discovery Officer

Carter J. King

Executive Vice President of Business Development

Matthew M. Gosling J.D.

Executive Vice President & General Counsel

Management

Asif AliCFO

Executive Vice President & Chief Financial Officer

Mohammad Masjedizadeh Ph.D.CTO

Executive Vice President & Chief Technology Officer

Suneel K. Gupta Ph.D.

Executive Vice President of Clinical Development

Newman Yeilding

Executive Vice President, Chief Scientific Officer

Carena Spivey

Head of HR & Senior Vice President of Human Resources

Ashok Bhandari Ph.D.

EVice President & Chief Discovery Officer

Carter J. King

Executive Vice President of Business Development

Matthew M. Gosling J.D.

Executive Vice President & General Counsel

Total 8 executives

PTGX Frequently asked questions

What is Protagonist Therapeutics, Inc. (PTGX) Stock Price?

Current stock price of Protagonist Therapeutics, Inc. (PTGX) stock is $146.49. The stock price is -0.85% lower in the session. The intraday range can be seen from this page. Volume of Protagonist Therapeutics, Inc. (PTGX) stock is 534.12K.

Last updated at 01 Sept 2026, 08:00 pm.

Why is the Protagonist Therapeutics, Inc. (PTGX) stock price going up or down today?

The stock price of Protagonist Therapeutics, Inc. (PTGX) can change with earnings, company news, and overall market sentiment. Protagonist Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Protagonist Therapeutics, Inc. stock expensive at its current price?

Whether Protagonist Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for PTGX on this page is 142.22. EPS on this page is 1.03. Compare those figures with peers and growth expectations before deciding if the current Protagonist Therapeutics, Inc. price is justified.

How has the stock price of Protagonist Therapeutics, Inc. (PTGX) performed historically?

Historical performance for Protagonist Therapeutics, Inc. (PTGX) is shown on the price chart on this page. Review multi-period moves alongside volume to see how PTGX reacted to past earnings and market events.

Should I buy Protagonist Therapeutics, Inc. (PTGX) stock, at this price?

Buying Protagonist Therapeutics, Inc. (PTGX) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.